These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14758817)

  • 41. "For all my family's sake, I should go and find out": an Australian report on genetic counseling and testing uptake in individuals at high risk of breast and/or ovarian cancer.
    Wakefield CE; Ratnayake P; Meiser B; Suthers G; Price MA; Duffy J; Tucker K;
    Genet Test Mol Biomarkers; 2011 Jun; 15(6):379-85. PubMed ID: 21254855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
    Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives.
    Evans DG; Binchy A; Shenton A; Hopwood P; Craufurd D
    Clin Genet; 2009 Feb; 75(2):124-32. PubMed ID: 19215246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
    Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
    Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution.
    Lee SC; Bernhardt BA; Helzlsouer KJ
    Cancer; 2002 Mar; 94(6):1876-85. PubMed ID: 11920551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 and sex ratio.
    Struewing JP; Hartge P; Wacholder S; Tucker MA; Greene MH
    Eur J Hum Genet; 2004 Aug; 12(8):663-7. PubMed ID: 15114373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
    Moss HA; Samimi G; Havrilesky LJ; Sherman ME; Myers ER
    Genet Epidemiol; 2018 Feb; 42(1):117-122. PubMed ID: 29193313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
    JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
    Wagner Costalas J; Itzen M; Malick J; Babb JS; Bove B; Godwin AK; Daly MB
    Am J Med Genet C Semin Med Genet; 2003 May; 119C(1):11-8. PubMed ID: 12704633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    Randall TC; Armstrong K
    Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
    Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
    Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
    Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
    Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
    Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.